Michael R Folkert1, Dana L Casey2, Sean L Berry3, Aimee Crago4, Nicola Fabbri5, Samuel Singer4, Kaled M Alektiar6. 1. Department of Radiation Oncology, UT Southwestern Medical Center, Dallas, USA. 2. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3. Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, USA. 4. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA. 5. Department of Orthopedic Surgery, Memorial Sloan Kettering Cancer Center, New York, USA. 6. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. alektiak@mskcc.org.
Abstract
PURPOSE: This study was designed to compare the observed risk of femoral fracture in primary soft-tissue sarcoma (STS) of the thigh/groin treated with intensity-modulated radiation therapy (IMRT) to expected risk calculated using the Princess Margaret Hospital (PMH) nomogram. METHODS: Expected femoral fracture risk was calculated by using the PMH nomogram. Cumulative risk of fracture was estimated by using Kaplan-Meier statistics. Prognostic factors were assessed with univariate and multivariate analysis using Cox's stepwise regression. RESULTS: Between February 2002 and December 2010, 92 consecutive eligible patients were assessed. Median follow-up was 73 months (106 months in surviving patients). IMRT was delivered preoperatively (50 Gy) in 13 (14%) patients and postoperatively in 79 (86%) patients (median dose, 63 Gy; range, 59.4-66.6 Gy). The observed crude risk of fractures was 6.5% compared with 25.6% expected risk from the nomogram; the cumulative risk of fracture using IMRT at 5 years was 6.7% (95% CI 2.8-16.0%). The median time to fracture was 23 months (range, 6.9-88.6). Significant predictors of fracture on univariate analysis were age ≥ 60 years (p = 0.03), tumor location in the anterior thigh (p = 0.008), and periosteal stripping to > 20 cm (p < 0.0001). On multivariate analysis, age ≥ 60 years and periosteal stripping > 20 cm retained significance (p = 0.04 and p = 0.009, respectively). CONCLUSIONS: In this study, the cumulative risk of femur fracture in patients treated with IMRT (6.7%) is less than the expected risk using the PMH nomogram (25.6%). Established predictors of femur fracture, such as gender, tumor size, and dose of RT, seem to have less impact on fracture risk when using IMRT.
PURPOSE: This study was designed to compare the observed risk of femoral fracture in primary soft-tissue sarcoma (STS) of the thigh/groin treated with intensity-modulated radiation therapy (IMRT) to expected risk calculated using the Princess Margaret Hospital (PMH) nomogram. METHODS: Expected femoral fracture risk was calculated by using the PMH nomogram. Cumulative risk of fracture was estimated by using Kaplan-Meier statistics. Prognostic factors were assessed with univariate and multivariate analysis using Cox's stepwise regression. RESULTS: Between February 2002 and December 2010, 92 consecutive eligible patients were assessed. Median follow-up was 73 months (106 months in surviving patients). IMRT was delivered preoperatively (50 Gy) in 13 (14%) patients and postoperatively in 79 (86%) patients (median dose, 63 Gy; range, 59.4-66.6 Gy). The observed crude risk of fractures was 6.5% compared with 25.6% expected risk from the nomogram; the cumulative risk of fracture using IMRT at 5 years was 6.7% (95% CI 2.8-16.0%). The median time to fracture was 23 months (range, 6.9-88.6). Significant predictors of fracture on univariate analysis were age ≥ 60 years (p = 0.03), tumor location in the anterior thigh (p = 0.008), and periosteal stripping to > 20 cm (p < 0.0001). On multivariate analysis, age ≥ 60 years and periosteal stripping > 20 cm retained significance (p = 0.04 and p = 0.009, respectively). CONCLUSIONS: In this study, the cumulative risk of femur fracture in patients treated with IMRT (6.7%) is less than the expected risk using the PMH nomogram (25.6%). Established predictors of femur fracture, such as gender, tumor size, and dose of RT, seem to have less impact on fracture risk when using IMRT.
Authors: Christopher P Cannon; Matthew T Ballo; Gunar K Zagars; Attiqa N Mirza; Patrick P Lin; Valerae O Lewis; Alan W Yasko; Robert S Benjamin; Peter W T Pisters Journal: Cancer Date: 2006-11-15 Impact factor: 6.860
Authors: Ginger E Holt; Anthony M Griffin; Melania Pintilie; Jay S Wunder; Charles Catton; Brian O'Sullivan; Robert S Bell Journal: J Bone Joint Surg Am Date: 2005-02 Impact factor: 5.284
Authors: Linda Hong; Kaled M Alektiar; Margie Hunt; Ennapadam Venkatraman; Steven A Leibel Journal: Int J Radiat Oncol Biol Phys Date: 2004-07-01 Impact factor: 7.038
Authors: Colleen I Dickie; Amy L Parent; Anthony M Griffin; Sharon Fung; Peter W M Chung; Charles N Catton; Peter C Ferguson; Jay S Wunder; Robert S Bell; Michael B Sharpe; Brian O'Sullivan Journal: Int J Radiat Oncol Biol Phys Date: 2009-04-11 Impact factor: 7.038
Authors: Yair Gortzak; Gina A Lockwood; Ashish Mahendra; Ying Wang; Peter W M Chung; Charles N Catton; Brian O'Sullivan; Benjamin M Deheshi; Jay S Wunder; Peter C Ferguson Journal: Cancer Date: 2010-03-15 Impact factor: 6.860
Authors: Meredith K Bartelstein; Divya Yerramilli; Alexander B Christ; Shachar Kenan; Koichi Ogura; Tomohiro Fujiwara; Nicola Fabbri; John H Healey Journal: Sarcoma Date: 2021-03-15
Authors: Cameron M Callaghan; M M Hasibuzzaman; Samuel N Rodman; Jessica E Goetz; Kranti A Mapuskar; Michael S Petronek; Emily J Steinbach; Benjamin J Miller; Casey F Pulliam; Mitchell C Coleman; Varun V Monga; Mohammed M Milhem; Douglas R Spitz; Bryan G Allen Journal: Cancers (Basel) Date: 2020-08-12 Impact factor: 6.639
Authors: Rémi Bourdais; Samir Achkar; Charles Honoré; Matthieu Faron; Andrea Cavalcanti; Guillaume Auzac; Carine Ngo; Leila Haddag-Miliani; Benjamin Verret; Sarah Dumont; Eric Deutsch; Axel Le Cesne; Olivier Mir; Cécile Le Péchoux; Antonin Levy Journal: Clin Transl Radiat Oncol Date: 2021-06-04